Sign in to view content

End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD

Aleksandra V. Rachitskaya, MD, FASRS

Video
Published 2022

Related

Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Long-term Experience With Intravitreal Anti-VEGF Treatment in Patients With nAMD: Analysis of IRIS® (Intelligent Research in Sight) Registry Database
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2021
Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more